Risk stratification for synchronous/metachronous recurrence after endoscopic submucosal dissection for Barrett's esophageal adenocarcinoma using the length of Barrett's esophagus
- PMID: 38607537
- DOI: 10.1007/s10388-024-01058-8
Risk stratification for synchronous/metachronous recurrence after endoscopic submucosal dissection for Barrett's esophageal adenocarcinoma using the length of Barrett's esophagus
Abstract
Background: In Japan, the standard management of Barrett's esophageal adenocarcinoma after endoscopic submucosal dissection involves follow-up; however, multifocal synchronous/metachronous lesions are sometimes observed after endoscopic submucosal dissection. Risk stratification of multifocal cancer facilitates appropriate treatment, including eradication of Barrett's esophagus in high-risk cases; however, no effective risk stratification methods have been established. Thus, we identified the risk factors for multifocal cancer and explored risk-stratified treatment strategies for residual Barrett's esophagus.
Methods: We retrospectively reviewed the data of 97 consecutive patients with superficial Barrett's esophageal adenocarcinomas who underwent curative resection with endoscopic submucosal dissection. Multifocal cancer was defined by the presence of synchronous/metachronous lesions during follow-up. We used Cox regression analysis to identify the risk factors for multifocal cancer and subsequently analyzed differences in cumulative incidences.
Results: The cumulative incidences of multifocal cancer at 1, 3, and 5 years were 4.4%, 8.6%, and 10.7%, respectively. Significant risk factors for multifocal cancer were increased circumferential and maximal lengths of Barrett's esophagus. The cumulative incidences of multifocal cancer at 3 years were lower for patients with circumferential length < 4 cm and maximal length < 5 cm (2.9% and 1.2%, respectively) than for patients with circumferential length ≥ 4 cm and maximal length ≥ 5 cm (51.5% and 49.1%, respectively).
Conclusions: Risk stratification of multifocal cancer using length of Barrett's esophagus was effective. Further multicenter prospective studies are needed to substantiate our findings.
Keywords: Adenocarcinoma; Barrett’s esophagus; Disease eradication; Endoscopic submucosal dissection; Metachronous neoplasms.
© 2024. The Author(s), under exclusive licence to The Author(s) under exclusive licence to The Japan Esophageal Society.
Similar articles
-
Long- vs short-segment Barrett's esophagus-derived adenocarcinoma: clinical features and outcomes of endoscopic submucosal dissection.Surg Endosc. 2024 Jul;38(7):3636-3644. doi: 10.1007/s00464-024-10888-7. Epub 2024 May 20. Surg Endosc. 2024. PMID: 38769185
-
Treatment Outcomes of Endoscopic Submucosal Dissection for Adenocarcinoma Originating from Long-Segment Barrett's Esophagus versus Short-Segment Barrett's Esophagus.Digestion. 2018;97(4):316-323. doi: 10.1159/000486197. Epub 2018 Mar 14. Digestion. 2018. PMID: 29539629
-
Management of Nodular Neoplasia in Barrett's Esophagus: Endoscopic Mucosal Resection and Endoscopic Submucosal Dissection.Gastrointest Endosc Clin N Am. 2017 Jul;27(3):461-470. doi: 10.1016/j.giec.2017.02.004. Epub 2017 Mar 22. Gastrointest Endosc Clin N Am. 2017. PMID: 28577767 Review.
-
Endoscopic Treatment of Early Barrett's Adenocarcinoma and Dysplasia: Focus on Submucosal Cancer.Digestion. 2019;99(4):293-300. doi: 10.1159/000492217. Epub 2018 Sep 3. Digestion. 2019. PMID: 30176662
-
Endoscopic resection (endoscopic submucosal dissection/endoscopic mucosal resection) for superficial Barrett's esophageal cancer.Dig Endosc. 2013 Mar;25 Suppl 1:20-8. doi: 10.1111/den.12047. Dig Endosc. 2013. PMID: 23480400 Review.
References
MeSH terms
Supplementary concepts
LinkOut - more resources
Medical